

Multiple Sclerosis Therapies Market: The Evolution of a New Subspecialty will reach \$22.99 Billion by 2026

Significant rise in number of pipeline drugs is a key factor that contributes toward the growth of the global multiple sclerosis therapies market

PORTLAND, OREGON, UNITED STATES, December 22, 2021 /EINPresswire.com/ -- According to the report by Allied Market Research, titled, "[Multiple Sclerosis Therapies Market](#) by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019–2026". The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

The global multiple sclerosis (MS) therapies market was valued at \$22.99 billion in 2018, and is projected to reach \$28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026.

For Right Perspective and Competitive Insights, Get Sample Report at:
<https://www.alliedmarketresearch.com/request-sample/1438>

Increase in number of pipeline drugs, surge in patient population, and rise in number of patient assistance programs (PAPs) drive the global multiple sclerosis therapies market. However, unspecified etiology of the disease restrains the market growth. On the other hand, the introduction of disease-modifying drugs and usage of off-label drugs will create new opportunities in the coming years.

Comprehensive competitive analysis and profiles of major market players, such as

Bayer AG
Biogen
Bristol-Myers Squibb Company
ABBVIE INC.
F. Hoffmann-La Roche Ltd.
Merck KGaA
Novartis AG
Pfizer Inc.
SANOFI

Teva Pharmaceutical Industries Ltd.

Significant rise in number of pipeline drugs is a key factor that contributes toward the growth of the global multiple sclerosis therapies market along with increase in patient base suffering from multiple sclerosis. Furthermore, surge in number of patient assistance programs and similar initiatives undertaken by the government of various countries are anticipated to further boost the demand for multiple sclerosis therapies in coming future.

Key Findings Of The Study:

North America garnered 36.33% share of the global MS therapies market in 2018.

By type, immunosuppressants segment is anticipated to grow with the highest CAGR throughout the forecast period.

The injectable segment accounted for 33.10% share of the market in 2018.

North America to maintain its dominant by 2026-

Based on region, North America, accounted for the highest share based on revenue, holding for nearly two-fifths of the total share of the global multiple sclerosis therapies market in 2018, owing to rise in U.S. FDA approvals for medications used in the treatment of MS and improved healthcare system in this region. However, LAMEA is estimated to portray the fastest CAGR of 3.1% from 2019 to 2026, owing to the high prevalence of MS in the Middle East countries.

Get upto 25% Discount: <https://www.alliedmarketresearch.com/purchase-enquiry/1438>

Table of Content

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. KEY FINDINGS

3.2.1. Top investment pockets

3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING

3.4. PORTER'S FIVE FORCES ANALYSIS

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities...

FREQUENTLY ASKED QUESTIONS?

Q1. What is the market value of Multiple Sclerosis Therapies Market report in forecast period?

Q2. What would be forecast period in the market report?

Q3. What is the market value of Multiple Sclerosis Therapies Market in 2020?

Q4. Which is base year calculated in the Multiple Sclerosis Therapies Market report?

Q5. Does the Multiple Sclerosis Therapies Market company is profiled in the report?

Q6. Which are the top companies hold the market share in Multiple Sclerosis Therapies Market?

Q7. Does the Multiple Sclerosis Therapies Market report provides Value Chain Analysis?

Q8. What are the key trends in the Multiple Sclerosis Therapies Market report?

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: <https://www.alliedmarketresearch.com/avenue/trial/starter>

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

[Colorectal Cancer Liquid Biopsy Market](#) - Global Opportunity Analysis and Industry Forecast, 2020-2028

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Analytics LLP

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/558964693>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.